Drug Overview

Serine threonine kinase inhibitor CBP501 is a modern, experimental medication designed to treat difficult-to-treat cancers. It is a synthetic peptide, which means it is a laboratory-made protein chain. This drug is part of an advanced group of medicines that target the internal control systems of cancer cells to make them more vulnerable to other treatments.

Because it is an investigational drug, it is currently available only through clinical trials. It is not something that can be purchased at a regular pharmacy. It is being tested primarily as a combination therapy, meaning it is used alongside standard chemotherapy and immunotherapy to improve their success rates.

• Generic name: Serine threonine kinase inhibitor CBP501 (also known as CBP501)
• US Brand names: None (Investigational drug)
• Drug Class: Serine/threonine kinase inhibitor, G2 checkpoint inhibitor
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Investigational (Granted Orphan Drug Designation for certain cancers)

What Is It and How Does It Work? (Mechanism of Action)

CBP501 is classified as a Targeted Therapy and a Smart Drug. It is unique because it does not just kill cells; it disrupts the specific “repair manual” that cancer cells use to survive chemotherapy.

At the molecular level, every cell goes through a cycle of growth and division. When chemotherapy damages a cell’s DNA, healthy cells stop their growth at a “checkpoint” called G2 to fix the damage. Many cancer cells have a broken G1 checkpoint, so they rely almost entirely on the G2 checkpoint to survive.

CBP501 works by targeting and blocking specific proteins called serine/threonine kinases, including one called Calmodulin-binding protein. By inhibiting these kinases, CBP501 “unlocks” the G2 checkpoint. This forces the cancer cell to keep dividing even though its DNA is badly damaged by chemotherapy. Because the cancer cell cannot stop to fix itself, it collapses and dies.

Additionally, CBP501 has Immunotherapy characteristics. It helps increase the accumulation of chemotherapy drugs inside the tumor and stimulates the immune system by making the cancer cells more “visible” to the body’s natural T-cells. This dual action—breaking the repair system and alerting the immune system—makes it a powerful potential tool in oncology.

FDA-Approved Clinical Indications

Because CBP501 is currently an investigational drug, it does not have official FDA-approved indications for the general public. It is being studied in clinical trials for the following conditions:

Oncological uses

• Investigational treatment for metastatic exocrine pancreatic cancer (in combination with cisplatin and nivolumab).
• Investigational treatment for relapsed or refractory malignant pleural mesothelioma.
• Investigational treatment for advanced solid tumors that have not responded to standard therapies.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, CBP501 is given as a liquid through a needle into a vein. The dosage is usually calculated based on the patient’s body surface area.

Dose Adjustments

There are no established dose starting rules for renal or hepatic insufficiency outside of trial protocols. However, if a patient develops severe kidney stress or liver enzyme spikes, the research doctors will pause or lower the dose. Patients must meet specific kidney and liver health scores before they are allowed to receive each dose.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2026 have focused on the Phase 2 trial results for pancreatic cancer.

Numerical data from these studies are very encouraging. In a major trial for patients with third-line metastatic pancreatic cancer—meaning they had already failed two other types of treatment—the combination of CBP501, cisplatin, and nivolumab showed a significant benefit. The trial reported an overall survival rate that was higher than historical averages for this stage of the disease. Specifically, the disease control rate reached approximately 40 percent in certain patient groups. While it is still in testing, these results suggest that CBP501 can help slow down disease progression even when other drugs have stopped working.

Safety Profile and Side Effects

CBP501 has a safety profile that is generally considered manageable, but because it is given with chemotherapy, side effects can be combined.

Black Box Warning

There is no official FDA Black Box Warning for CBP501 because it is an investigational drug.

Common side effects

These side effects are seen in greater than 10 percent of patients:

• Nausea and vomiting
• Feeling very tired (fatigue)
• Skin rash or itching
• Infusion-related reactions (fever or chills during the drip)
• Decreased appetite

Serious adverse events

• Severe allergic reactions (anaphylaxis)
• Significant drops in white blood cell or platelet counts
• Increased liver enzymes (hepatotoxicity)
• Potential kidney stress when combined with cisplatin

Management strategies

To manage infusion reactions, doctors often give patients allergy medications (antihistamines) before the drip starts. For nausea, standard anti-nausea drugs are used. Because CBP501 is often used with cisplatin, patients are given large amounts of IV fluids (hydration) to protect their kidneys. If blood counts drop too low, the next dose will be delayed until the bone marrow recovers.

Research Areas

CBP501 is a major topic of interest in the study of the “tumor microenvironment.” Researchers are looking at how this drug can turn “cold” tumors (cancers the immune system ignores) into “hot” tumors (cancers the immune system attacks). There is also active research exploring whether CBP501 can target “cancer stem cells,” which are the stubborn cells that often cause a tumor to grow back. By disrupting the G2 checkpoint in these stem cells, scientists hope to make regenerative immunotherapies more effective at permanently clearing the cancer.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Complete blood count (CBC) to check white blood cells, red cells, and platelets.
• Comprehensive metabolic panel to check liver and kidney function.
• Physical exam to establish a baseline of general health.

Precautions during treatment

Patients must be prepared for a long day at the clinic, as the combination of drugs usually requires several hours of infusion and observation. It is vital to stay very hydrated to help the kidneys process the medicine.

Do’s and Don’ts list

• Do tell your medical team immediately if you feel itchy, hot, or have trouble breathing during the infusion.
• Do drink at least 8 to 10 glasses of water on the day before and the day of your treatment.
• Do report any new skin rashes, even if they seem minor.
• Don’t ignore a fever; call your oncology team right away if your temperature rises.
• Don’t take any new herbal supplements or over-the-counter vitamins without asking your trial doctor first.
• Don’t skip your scheduled blood tests, as they are the only way to catch kidney or liver stress early.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. CBP501 is an investigational medication and is not approved by the FDA for the treatment of any disease. Always consult with a qualified oncologist or healthcare professional before participating in a clinical trial or starting a new medical treatment.